Search research articles
Contact Us
Filters
Showing results (11-20 of 54) with videos related to
Page
of 6
Sort By:
Rheumatology (Oxford, England)
|
December 7, 2002
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses
D Aletaha, J S Smolen
Clinical and Experimental Rheumatology
|
February 19, 2004
DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease
D Aletaha, J S Smolen
Clinical and Experimental Rheumatology
|
November 7, 2006
What should be our treatment goal in rheumatoid arthritis today?
J S Smolen, D Aletaha
Zeitschrift Fur Rheumatologie
|
February 24, 2006
[Measuring disease activity for rheumatoid arthritis]
D Aletaha, T Stamm, J Smolen
Annals of the Rheumatic Diseases
|
April 16, 2003
Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis
D Aletaha, T Kapral, J S Smolen
Annals of the Rheumatic Diseases
|
January 14, 2009
Does damage cause inflammation? Revisiting the link between joint damage and inflammation
J S Smolen, D Aletaha, G Steiner
Clinical and Experimental Rheumatology
|
November 21, 2007
Disease activity measures for rheumatoid arthritis
M Dougados, D Aletaha, P van Riel
Annals of the Rheumatic Diseases
|
July 27, 2016
Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression
D Aletaha, F Alasti, J S Smolen
Clinical and Experimental Rheumatology
|
November 7, 2006
Complexities in defining remission in rheumatic diseases
T Pincus, A Kavanaugh, D Aletaha, et al.
Arthritis Research & Therapy
|
July 6, 2017
Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
M Schoels, F Alasti, J S Smolen, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 54) with videos related to
Sort By:
Page
of 6
Rheumatology (Oxford, England)
|
December 7, 2002
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses
D Aletaha, J S Smolen
Clinical and Experimental Rheumatology
|
February 19, 2004
DMARD use in early rheumatoid arthritis. Lessons from observations in patients with established disease
D Aletaha, J S Smolen
Clinical and Experimental Rheumatology
|
November 7, 2006
What should be our treatment goal in rheumatoid arthritis today?
J S Smolen, D Aletaha
Zeitschrift Fur Rheumatologie
|
February 24, 2006
[Measuring disease activity for rheumatoid arthritis]
D Aletaha, T Stamm, J Smolen
Annals of the Rheumatic Diseases
|
April 16, 2003
Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis
D Aletaha, T Kapral, J S Smolen
Annals of the Rheumatic Diseases
|
January 14, 2009
Does damage cause inflammation? Revisiting the link between joint damage and inflammation
J S Smolen, D Aletaha, G Steiner
Clinical and Experimental Rheumatology
|
November 21, 2007
Disease activity measures for rheumatoid arthritis
M Dougados, D Aletaha, P van Riel
Annals of the Rheumatic Diseases
|
July 27, 2016
Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression
D Aletaha, F Alasti, J S Smolen
Clinical and Experimental Rheumatology
|
November 7, 2006
Complexities in defining remission in rheumatic diseases
T Pincus, A Kavanaugh, D Aletaha, et al.
Arthritis Research & Therapy
|
July 6, 2017
Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
M Schoels, F Alasti, J S Smolen, et al.
Page
of 6